# Tokyo National Hospital

**Type:** Institutions  
**Canonical URL:** https://scholariq.org/institutions/tokyo-national-hospital/

## Facts

| Field | Value |
| --- | --- |
| Avg h-index | 70.5 |
| Citations | 686,312 |
| City | Tokyo |
| Country | JP |
| Description | Tokyo National Hospital is a research organisation in Tokyo, JP. OpenAlex records 10,505 works and 686,312 citations for it. 1,573 researchers list it as their most recent affiliation. |
| Homepage | http://www.hosp.go.jp/~tokyo/ |
| OpenAlex ID | https://openalex.org/I4210156366 |
| Researchers | 1,573 |
| ROR ID | https://ror.org/05asn5035 |
| Type | healthcare |
| Works | 10,505 |

## University papers

- [Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer](https://scholariq.org/papers/japanese-society-for-cancer-of-the-colon-and-rectum-jsccr-guidelines-2016-for/)
- [Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer](https://scholariq.org/papers/japanese-society-for-cancer-of-the-colon-and-rectum-jsccr-guidelines-2019-for/)
- [Deep learning can predict microsatellite instability directly from histology in gastrointestinal cancer](https://scholariq.org/papers/deep-learning-can-predict-microsatellite-instability-directly-from-histology-in/)
- [Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators](https://scholariq.org/papers/whole-genome-sequencing-of-liver-cancers-identifies-etiological-influences-on/)
- [Adoptive immunotherapy to lower postsurgical recurrence rates of hepatocellular carcinoma: a randomised trial](https://scholariq.org/papers/adoptive-immunotherapy-to-lower-postsurgical-recurrence-rates-of-hepatocellular/)
- [Randomized Phase III Study of Gemcitabine Plus S-1, S-1 Alone, or Gemcitabine Alone in Patients With Locally Advanced and Metastatic Pancreatic Cancer in Japan and Taiwan: GEST Study](https://scholariq.org/papers/randomized-phase-iii-study-of-gemcitabine-plus-s-1-s-1-alone-or-gemcitabine/)

## University top topics

Showing 8 of 25.

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Gastric Cancer Management and Outcomes](https://scholariq.org/topics/gastric-cancer-management-and-outcomes/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Lymphoma Diagnosis and Treatment](https://scholariq.org/topics/lymphoma-diagnosis-and-treatment/)
- [Esophageal Cancer Research and Treatment](https://scholariq.org/topics/esophageal-cancer-research-and-treatment/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.